Anteris Technologies Global Corp. Common Stock logo

AVRAnteris Technologies Global Corp. Common Stock

NASDAQ · Healthcare · Medical Instruments & Supplies

$8.78

+$0.33 (+3.91%)

Anteris Technologies Global Corp. Common Stock (AVR) is a medical instruments & supplies company listed on NASDAQ. It is led by Wayne Geoffrey Paterson, based in Toowong Tower, Toowong, QLD, Australia, 4066, with about 136 employees. Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.

Latest reported AVR revenue for 2025-09-30 was $429.0K. Net income was -$22.2M. Revenue was down 30.6% from 2025-06-30 to 2025-09-30. AVR currently screens at market cap $287.2M.

Use this AVR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the AVR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the AVR SEC filings page. Lician reads the product cache first so this HTML stays unique to Anteris Technologies Global Corp. Common Stock even when a live quote feed is slow.

About Anteris Technologies Global Corp. Common Stock

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.

AVR Key Statistics

Market Cap

$287.16M

Volume

515,177

Previous Close

$8.80

Day Range

$8.72$8.96

00

EPS

-$0.62

Revenue

$429.00K

Net Income

-$22.21M

Gross Profit

$0.00

Free Cash Flow

$0.00

Revenue Growth

-30.6%

Profit Margin

-5176.9%

Employees

136

AVR Financials

Annual income statement in USD. Latest reported periods first.

AVR annual income statement across FY2025, FY2025, FY2025, FY2024, FY2024
LineFY2025FY2025FY2025FY2024FY2024
Revenue$429.00K$618.00K$556.00K$769.00K$632.00K
Cost of Revenue$0.00$0.00$0.00$0.00$0.00
Gross Profit$0.00$0.00$0.00$0.00$0.00
Operating Income$0.00$0.00$0.00$0.00$0.00
Net Income-$22.21M-$21.06M-$21.93M-$21.79M-$18.82M
EPS (Diluted)-$0.62-$0.58-$0.61-$1.07-$0.98

Total Assets

$19.07M

Total Debt

$0.00

Shareholders' Equity

$0.00

Cash & Equivalents

$0.00

Operating Cash Flow

-$59.28M

Free Cash Flow

$0.00

Anteris Technologies Global Corp. Common Stock Company Information

Vice Chairman & CEO
Wayne Geoffrey Paterson
Headquarters
Toowong Tower, Toowong, QLD, Australia, 4066
Phone
61 7 3152 3200
IPO / Founded
2024-12-13
Industry
Medical Instruments & Supplies
Data Updated:

Upcoming Events for AVR